Mirum (NASDAQ: MIRM) COO sells shares after RSU vesting

Q: What insider transaction did Mirum Pharmaceuticals (MIRM) report for Peter Radovich?

Mirum Pharmaceuticals reported that President and COO Peter Radovich had 4,167 restricted stock units convert into common stock on January 21, 2026 , and then sold 2,382 shares of common stock on January 22, 2026 .

Q: At what price were Mirum Pharmaceuticals (MIRM) shares sold in this Form 4?

The Form 4 shows that 2,382 shares of Mirum common stock were sold at an average price of $93.3252 per share on January 22, 2026 .

Q: Why did the Mirum Pharmaceuticals (MIRM) executive sell shares in this filing?

The footnotes state that the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units, indicating a tax-related sale rather than an open-market discretionary divestment.

Q: What are the vesting terms for the Mirum Pharmaceuticals (MIRM) restricted stock units in this Form 4?

The filing explains that one-third of the shares subject to the restricted stock units vest on each anniversary of January 21, 2025 , so the award is fully vested on the three-year anniversary of that vesting commencement date.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. executive Peter Radovich, the company’s President and COO, reported routine equity compensation activity. On January 21, 2026, 4,167 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0 per share. Each restricted stock unit represents a right to receive one share of common stock or its cash equivalent. Following this conversion, he held 23,061 shares of common stock, which includes 222 shares acquired under the company’s employee stock purchase plan.

On January 22, 2026, Radovich sold 2,382 shares of Mirum common stock at an average price of $93.3252 per share, with the shares sold to cover tax withholding obligations related to the RSU vesting. After the sale, he beneficially owned 20,679 shares of common stock directly, and 8,333 restricted stock units remained outstanding, scheduled to vest in equal annual installments through the third anniversary of January 21, 2025.

Insider Trade Summary

Net Seller: 2,382 shares ($222,301)

Net Sell 3 txns

Insider Radovich Peter

Role PRESIDENT AND COO

Sold 2,382 shs ($222K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,382	$93.3252	$222K
Exercise	Restricted Stock Units	4,167	$0.00	--
Exercise	Common Stock	4,167	$0.00	--

Holdings After Transaction: Common Stock — 20,679 shares (Direct); Restricted Stock Units — 8,333 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Includes 222 shares of common stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Form 4 Insider Transactions: What Each Field Means →

01/23/2026 - 05:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radovich Peter

(Last)

(First)

(Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY

94404

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND COO

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/21/2026		M		4,167	A	⁽¹⁾	23,061⁽²⁾	D
Common Stock	01/22/2026		S⁽³⁾		2,382	D	$93.3252	20,679	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/21/2026		M			4,167	⁽⁴⁾	⁽⁴⁾	Common Stock	4,167	$0	8,333	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

2. Includes 222 shares of common stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan.

3. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

4. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Mirum Pharmaceuticals (MIRM) report for Peter Radovich?

Mirum Pharmaceuticals reported that President and COO Peter Radovich had 4,167 restricted stock units convert into common stock on January 21, 2026, and then sold 2,382 shares of common stock on January 22, 2026.

At what price were Mirum Pharmaceuticals (MIRM) shares sold in this Form 4?

The Form 4 shows that 2,382 shares of Mirum common stock were sold at an average price of $93.3252 per share on January 22, 2026.

Why did the Mirum Pharmaceuticals (MIRM) executive sell shares in this filing?

The footnotes state that the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units, indicating a tax-related sale rather than an open-market discretionary divestment.

How many Mirum Pharmaceuticals (MIRM) shares does Peter Radovich hold after these transactions?

After the reported transactions, Peter Radovich beneficially owned 20,679 shares of Mirum common stock directly, and also held 8,333 restricted stock units that remain outstanding.

What are the vesting terms for the Mirum Pharmaceuticals (MIRM) restricted stock units in this Form 4?

The filing explains that one-third of the shares subject to the restricted stock units vest on each anniversary of January 21, 2025, so the award is fully vested on the three-year anniversary of that vesting commencement date.

Does the Mirum Pharmaceuticals (MIRM) Form 4 include shares from an employee stock purchase plan?

Yes. The Form 4 notes that Radovich’s beneficial ownership figure includes 222 shares of common stock acquired on November 10, 2025 through Mirum’s Employee Stock Purchase Plan.